% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hillengass:126728,
      author       = {J. Hillengass$^*$ and J. Stoll and C. M. Zechmann and C.
                      Kunz$^*$ and B. Wagner and C. Heiss$^*$ and M. Sumkauskaite
                      and T. M. Moehler and H. P. Schlemmer$^*$ and H. Goldschmidt
                      and S. Delorme$^*$},
      title        = {{T}he application of {G}adopentate-{D}imeneglumin has no
                      impact on progression free and overall survival as well as
                      renal function in patients with monoclonal plasma cell
                      disorders if general precautions are taken.},
      journal      = {European radiology},
      volume       = {25},
      number       = {3},
      issn         = {1432-1084},
      address      = {Berlin},
      publisher    = {Springer},
      reportid     = {DKFZ-2017-02756},
      pages        = {745 - 750},
      year         = {2015},
      abstract     = {The current analysis investigated the prognostic
                      significance of gadopentetate dimeglumine on survival and
                      renal function in patients with monoclonal plasma cell
                      disorders.In this study 263 patients who had received
                      gadopentetate dimeglumine within a prospective trial
                      investigating dynamic contrast-enhanced magnetic resonance
                      imaging (MRI) were compared with 335 patients who had
                      undergone routine, unenhanced MRI.We found no significant
                      prognostic impact of the application of contrast agent on
                      progression-free survival in patients with either monoclonal
                      gammopathy of undetermined significance, smouldering or
                      symptomatic myeloma and no significant prognostic impact on
                      overall survival in patients with symptomatic myeloma. Since
                      renal impairment is a frequent complication of myeloma, and
                      decreased renal function is associated with a higher risk of
                      complications in patients receiving contrast agents, we
                      evaluated the impact of contrast agent on renal function
                      after 1 year. In the present analysis the only significant
                      adverse impact on kidney function occurred in symptomatic
                      myeloma patients who already had impaired renal parameters
                      at baseline. Here, the renal function did not recover during
                      therapy, whereas it did so in patients with normal or only
                      slightly impaired renal function.If general recommendations
                      are adhered to, gadopentetate dimeglumine can be safely
                      applied in patients with monoclonal plasma cell disease.},
      keywords     = {Contrast Media (NLM Chemicals) / Gadolinium DTPA (NLM
                      Chemicals)},
      cin          = {E010 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25358594},
      doi          = {10.1007/s00330-014-3458-5},
      url          = {https://inrepo02.dkfz.de/record/126728},
}